Esperion Jumps 15% as BofA Double-upgrades Citing Near-term Upside
Esperion Extends Selloff as Daiichi Sankyo Dispute Prompts BofA Downgrade
Gilead Upgraded to Equal Weight at Barclays on Strong Execution in HIV, Kite
With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma
No Data